Pilot study for severe Takayasu artery inflammation
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 14 or older
- Your Takayasu arteritis is currently active (Kerr score 2 or higher)
- You have severe disease, such as very high blood pressure (over 180/110)
- Or you have significant artery narrowing in many artery branches (3 or more branches with over 70% narrowing)
- Or you have organ strain (NYHF class III–IV) or reduced kidney function (eGFR 15–60)
- You do NOT have certain other serious conditions that would block participation, like major uncontrolled organ failure or specific infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This trial tests a drug called secukinumab to see if it can help people with severe Takayasu arteritis, a rare disease that causes inflammation in the blood vessels. The drug works by blocking a protein that drives inflammation, which may reduce disease activity and help people lower their steroid dose.
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
This trial tests whether adding pirfenidone (a drug that reduces scarring) to your usual treatment helps limit blood vessel thickening and scarring in Takayasu arteritis. You must still have some signs of active disease despite being on standard therapy.
This trial is testing two new medications, vunakizumab and ivarmacitinib, to see if they are safe and effective at controlling active Takayasu's arteritis. These medicines work differently from your current treatment, so they might help reduce inflammation and prevent more damage to your blood vessels.
Hear when a new Takayasu Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.